Tranexamic Acid Contraindications
Tranexamic acid is absolutely contraindicated in patients with active intravascular clotting, subarachnoid hemorrhage, and known hypersensitivity to the drug. 1
Absolute Contraindications
Based on FDA labeling, the following are absolute contraindications where tranexamic acid must not be used:
- Active intravascular clotting - Due to the antifibrinolytic mechanism, TXA will worsen active thrombosis 1
- Subarachnoid hemorrhage - Anecdotal evidence indicates TXA may cause cerebral edema and cerebral infarction in these patients 1
- Known hypersensitivity to tranexamic acid - Anaphylactic reactions have been documented 1
Strong Relative Contraindications (Avoid Unless Life-Threatening Benefit)
Thromboembolic History
Avoid tranexamic acid in patients with history of thromboembolic events. The drug increases thrombotic risk through its antifibrinolytic properties 1. This includes:
- Prior venous thromboembolism (DVT/PE)
- Prior arterial thrombosis
- Recent myocardial infarction
- Recent stroke
- Recent PTCA or stent placement 2
Active Urinary Tract Bleeding
Microscopic or macroscopic hematuria is a contraindication - TXA causes clot formation in the urinary tract, leading to urinary obstruction 2, 3. Even microscopic hematuria has caused clinically significant problems 3.
Timing-Specific Contraindication in Postpartum Hemorrhage
Do not administer TXA beyond 3 hours after birth in postpartum hemorrhage - WHO guidelines indicate potential harm with no demonstrated benefit after this window, with effectiveness decreasing 10% for every 15-minute delay 4.
Situations Requiring Extreme Caution
Concomitant Prothrombotic Medications
Avoid combining TXA with 1:
- Factor IX complex concentrates
- Anti-inhibitor coagulant concentrates
- Hormonal contraceptives
- Other prothrombotic agents
Seizure History
Use with caution in patients with epilepsy - TXA can precipitate seizures, particularly at higher doses or with neuraxial administration 1, 2. Consider EEG monitoring if used.
Severe Renal Impairment
Not an absolute contraindication, but requires significant dose reduction 1:
- Creatinine 1.36-2.83 mg/dL: reduce to twice daily dosing
- Creatinine 2.83-5.66 mg/dL: reduce to once daily dosing
- Creatinine >5.66 mg/dL: reduce to every 48 hours or half-dose daily
Critical Safety Considerations
Route of Administration
Never administer intrathecally - Serious adverse reactions including seizures and cardiac arrhythmias occur with neuraxial administration 1. Clearly label syringes "IV ONLY."
Thromboembolic Risk Assessment
Recent evidence shows dose-dependent thrombotic risk, with marked increase at 4g dosing (HR 5.33) 5. In patients without shock, the absolute risk difference for thromboembolic events ranges from -0.2% to +4% 5.
Clinical Context Matters
While systematic reviews show TXA does not increase overall adverse event risk compared to placebo (RR 1.05,95% CI 0.99-1.12) 6, patient selection remains critical. The evidence suggests many traditional exclusion criteria (such as major comorbidities) may be overly restrictive 6, but the absolute contraindications listed above remain firm.
For high-risk patients requiring TXA (such as those with prior thromboembolism), intra-articular administration may be considered as an alternative to IV in appropriate surgical settings, as it appears to have similar efficacy with potentially lower systemic thrombotic risk 7.